Apnat (Apalutamide) is an oral androgen receptor inhibitor indicated for the treatment of non-metastatic and metastatic castration-resistant prostate cancer (CRPC). Prostate cancer is the second most commonly diagnosed cancer in men globally, with an estimated 1.4 million new cases reported each year, underscoring the need for effective targeted therapies.

Apalutamide works by selectively inhibiting androgen receptor signaling, a key driver of prostate cancer progression. Clinical evidence confirms that Apalutamide significantly improves metastasis-free survival (MFS) in high-risk CRPC patients receiving continuous androgen deprivation therapy (ADT).

Data from pivotal clinical trials demonstrate a 70% or greater reduction in the risk of metastasis or death compared to placebo, establishing Apalutamide as a standard treatment option in advanced prostate cancer management.

Apnat 60 mg tablets are manufactured in accordance with international quality and regulatory standards, providing a cost-effective alternative to branded therapy. Patients and buyers seeking competitive Apalutamide price in India benefit from affordable access without compromising on quality, making Apnat suitable for both domestic and international supply.

As a dependable Apalutamide manufacturer and exporter from India, The Indian Pharma ensures consistent quality, regulatory compliance, and reliable global distribution.